Pharmaceutical Executive-04-01-2003

Trending on PharmExec

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

MFN Is an Offer Pharma Can’t Refuse

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy